Acelyrin, Inc. (SLRN)
Company Description
ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
We are driven by our sense of urgency to bring life-changing therapies to patients globally, a core value that we refer to as “courageous caring.” Our initial focus is on the treatment of diseases with pathology related to excess activation of the immune system, an area where our management and team bring industry-leading expertise.
We acquired our portfolio of product candidates with the intent to develop and commercialize novel therapies that we believe may provide the opportunity to offer clinically meaningful, differentiated benefits for patients by improving upon the efficacy and/or safety of existing therapeutics directed against established targets, such as currently marketed anti-interleukin (IL)-17A agents, or by targeting new modalities.
In each case, our strategy is to identify candidates we believe are “diamonds in the rough,” where, based on molecule characteristics, our collective experience and expertise, and the evolving scientific and medical understanding, we can establish a clinical development plan that tests our hypotheses as to what those benefits could mean for patients.
Subsequently, we plan to utilize the results from initial clinical trials and the learnings we obtain from emerging biology to potentially expand the application of our candidates to other indications in which there are significant unmet needs.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 5, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Shao-Lee Lin, M.D., Ph.D. |
Contact Details
Address:
4149 Liberty Canyon Road Agoura Hills, CA 91301 United States | |
| Phone | (805) 730-0360 |
| Website | acelyrin.com |
Stock Details
| Ticker Symbol | SLRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001962918 |
| Employer ID | 85-2406735 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shao-Lee Lin, M.D., Ph.D. | Founder, Chief Executive Officer and Director |
| Mardi C. Dier | Chief Financial Officer and Chief Business Officer |
| Melanie Gloria | Chief Operating Officer |
| Mina Kim | Chief Legal and Administrative Officer |
| Ron Oyston | Chief People Officer |
| Paul M. Peloso, M.D. | Chief Medical Officer |
| Bruce C. Cozadd | Chair and Director |
| Dan Becker, M.D., Ph.D. | Director |
| Alan Colowick, M.D., M.P.H. | Director |
| Henry O. Gosebruch | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 19, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| May 19, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| May 9, 2023 | 8-K | Current Report |
| May 8, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 5, 2023 | 424B4 | Prospectus |
| May 4, 2023 | EFFECT | Notice of Effectiveness |
| May 4, 2023 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| May 4, 2023 | CERT | Certification by an exchange approving securities for listing |
| May 3, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |